Modality: Genetic Medicines

Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform

Boston, MA, April 7, 2026 — Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced a collaboration and license agreement with Biogen Inc. for the use of Alloy’s novel and proprietary AntiClastic™ ASO Platform. Through this collaboration, Biogen will apply the platform to advance antisense […]

Poster | Transient Cyclic Structured Oligonucleotides

Explore the science behind AntiClastic™ cyclic oligonucleotide design. Download the poster Contact Us Poster Overview: This poster highlights a novel approach to antisense architecture using transient cyclic structures designed to improve potency, reduce immune activation, and enhance the overall drug-like properties of RNA therapeutics. Download the poster to see how cyclic design can help overcome […]

Rethinking Antisense Architecture with Transient Cyclic Oligonucleotides for Next-Generation RNA Therapeutics

Author: Christian Cobaugh, CEO, Genetic Medicine Division at Alloy Therapeutics RNA therapeutics are moving from promise to reality. By operating upstream of protein targets and closer to the genetic root causes of many diseases, RNA medicines often offer treatment approaches that differ fundamentally from conventional small molecules or biologics. Antisense molecules have evolved from conceptual […]

Alloy Therapeutics Appoints Christian Cobaugh, Ph.D., as CEO of Alloy Genetic Medicines

BOSTON — January 6, 2026 — Alloy Therapeutics today announced the appointment of Christian Cobaugh, Ph.D., as Chief Executive Officer of Alloy Genetic Medicines.  Through its partnerships, the Genetic Medicines division is dedicated to developing AntiClastic™ nucleic acid medicines to treat diseases at the genetic level. Alloy’s AntiClastic technology is a proprietary cyclic nucleic acid […]

Alloy Therapeutics Launches Proprietary AntiClastic™ Antisense Oligonucleotide Platform to Make Potent Genetic Medicine

AntiClastic™ is a proprietary antisense oligonucleotide (ASO) platform developed by Alloy Therapeutics, designed to improve the potency and therapeutic index of antisense therapeutics targeting RNA. By combining improvements in primary sequence with novel spatial conformations of nucleic acids, the platform aims to enhance potency, reduce unintended interactions and inflammatory responses, and expand therapeutic opportunities for […]

Alloy Therapeutics Raises $42 Million Series D Financing to Accelerate Discovery Technology Development Across Biologic Modalities

Alloy Therapeutics secured $42 million in Series D financing to continue the expansion of its democratized ecosystem, which provides drug developers with open access to foundational antibody discovery platforms and services. This funding supports the company’s commitment to scaling its technology infrastructure, enabling scientific partners to advance biotherapeutic pipelines from discovery to the clinic. — […]

Alloy Therapeutics Ecosystem Offerings Go Intracellular Through Collaboration with Sudhir Agrawal in Genetic Medicines

Alloy Therapeutics’ intracellular genetic medicines platform provides drug developers with non-exclusive access to novel RNA-based chemistries and discovery technologies designed to target previously undruggable intracellular disease-associated RNAs. This ecosystem expands antibody discovery capabilities into antisense and immunomodulatory modalities to address complex therapeutic targets beyond the cell surface. –Through a partnership with antisense pioneer Agrawal’s Arnay […]

How Alloy Will Help the Drug Discovery Community Unlock the Therapeutic Potential of ASOs

Alloy Therapeutics is expanding into genetic medicines with its ASO Discovery Services group, offering democratized access to novel chemistries, bioinformatics-driven design, and ASO-antibody conjugates. Led by industry pioneers Dr. Sudhir Agrawal and Dr. Ben Chih, this initiative aims to overcome historical toxicity and accessibility barriers to unlock the full therapeutic potential of antisense oligonucleotides. Our […]

Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering

Alloy Therapeutics has enhanced its antibody discovery ecosystem by acquiring deepCDR Biologics, integrating advanced bioinformatics and deep learning capabilities into Alloy Discovery Services. This acquisition enables the rapid identification of high-affinity antibody candidates through machine learning-guided protein engineering and proprietary mammalian display technologies. The Basel, Switzerland-based deepCDR team and technology will strengthen Alloy’s antibody discovery […]